OR WAIT 15 SECS
Cetero Research announced it has completed more than 500 diabetes research studies in the past three years for both Type 1 and Type 2 diabetics, including complex clamp studies and studies in Phase I, II, III and IV. Cetero combines both pivotal pharmacokinetic studies and proof-of-concept studies in one study.
“Approximately eight percent of the U.S. population struggles with diabetes, and the numbers continue to grow,” said Dr. Troy McCall, CEO of Cetero Research. “According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are a record number of diabetes drugs in development to help the 20 million Americans battling this disease every day. We want to help get those treatments through proof-of-concept faster by providing a full range of services to pharmaceutical companies.”
Cetero runs first-in-human, pharmacokinetic, and proof-of concept studies in diabetics across three of its clinical facilities.
In one diabetes study for a global pharmaceutical company, Cetero randomized the first subject about three weeks after screening began. The final one of the 56 subjects was randomized 13 weeks after the first screening.
Cetero maintains recruiting strategies to build their database of potential study participants. These factors ensure studies are fully recruited, and start and conclude on-time. Cetero also works with a large endocrinology physician practice, which provides Cetero and its clients with access to additional patients.